WinstonWınston
Voyageur Pharmaceuticals logo

Voyageur Pharmaceuticals

VM.V
16
Drug Manufacturers - Specialty & Generic · Healthcare
Price
C$0.14
-0.01 (-3.57%)
Market Cap
C$24.2M
Exchange
Toronto Stock Exchange Ventures
Winston Score
16
Winston is worried
Weak fundamentals across most pillars.
Data as of Jul 25, 2026 · filings through Feb 28, 2026

Share count rising — dilution

+75.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 94.7M (2021) → 165.7M (2025)

Voyageur Pharmaceuticals is a small Canadian company focused on developing and commercializing specialty pharmaceutical products. Its main focus is on barium sulfate contrast agents — chemicals used in medical imaging scans to help doctors see inside the body more clearly. The company aims to supply these products to hospitals and medical imaging clinics, primarily in Canada.

Voyageur generates revenue through product sales, but it is currently a very early-stage company and spends far more money than it earns, as shown by its deeply negative margins. It operates mainly in Canada and has a very small market presence. The company's potential edge lies in owning domestic Canadian production of barium sulfate, which could reduce reliance on foreign suppliers — but the main risk is that it has not yet proven it can scale production, generate consistent revenue, or reach profitability, making it a highly speculative investment at this stage.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+34.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$907,668/ year

Rising (+216% vs prior year)

>1,000% of revenue

431.5x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

9.5%ownership

Insiders own a meaningful stake in the company

Cash Runway

~2 months

$89,709 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

Voyageur Pharmaceuticals is putting 7768% of revenue into R&D and that number is rising. That's 431.5x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
-657.8%
Thin — -657.8% gross margin
Operating Margin
-3255.3%
Losing money on operations — -3255.3%
ROCE
-89.5%
Weak — -89.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
N/A
Data not available
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-5489.9%
Burning cash (-5489.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.06
Conservative — low debt load (0.06)
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial